Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QCZ484 and Inclisiran in Hypertension and Hypercholesterolemia
NCT07610278Phase 2Recruiting
- Sponsor
- Novartis
- Start
- May 2026
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of QCZ484 in hypertension (HTN) and hypercholesterolemia (4 arms), sponsored by Novartis. Primary endpoints: Percent change from baseline of PCSK9 levels at Month 3 and Percent change from baseline of AGT levels at Month 3. Started May 2026; status: recruiting.
02
Drugs
QCZ484
03
Conditions
hypertension (HTN)hypercholesterolemia
Beyond the preview
Go deeper on NCT07610278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07610278.